Please assess the completion status of the following clinical trial:

Trial Title: SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of primary mucosal or acral/lentiginous melanoma~* Histologically documented stage III unresectable or IV metastatic melanoma~* ECOG Performance Status 0,1 or 2~* Estimated life expectancy of 6 months or greater~* 18 years of age or older~* Lab values as outlined in protocol~* Tumor blocks or slides must be available of either primary or metastatic tumor site for c-kit mutation testing~* Negative pregnancy test within 48 hours of starting treatment~* At least one measurable site of disease as defined by at least 1cm in greatest dimension~Exclusion Criteria:~* Severe and/or uncontrolled medical disease~* Pregnant or nursing mothers~* Known brain metastasis. History of or known spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or leptomeningeal disease on screening CT or MRI scan~* Less than 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or cervical carcinoma in situ~* Grade III/IV cardiac problems as defined by the New York Heart Association Criteria~* Ongoing cardiac dysrhythmias of grade 2 or greater, atrial fibrillation, QTc interval \>450msec for males of \>470 msec for females~* Hypertension that cannot be controlled by medication~* Any of the following within 12 months prior to starting treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism~* NCI CTCAE version 3.0 grade 3 hemorrhage within 4 weeks of starting the study treatment~* Concurrent treatment with warfarin~* Prior treatment with SU011248 or any other antiangiogenic agent~* No H2 blockers or proton pump inhibitors~* Known chronic liver disease~* Known HIV infection~* Previous radiotherapy to 25% or more of the bone marrow and/or radiation therapy within 4 weeks prior to study entry~* Major surgery within 4 weeks prior to study entry~* Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib (Type: EXPERIMENTAL): Cohort A participants received 50 mg sunitinib orally daily for 4 weeks followed by a two-week break from treatment. These 6-week cycles would be repeated until progression or unacceptable toxicity up to 1 year.~Cohort B participants received 37.5 mg sunitinib daily on a continuous basis until progression or unacceptable toxicity up to 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).